Asset
Glucagon
Xeris Biopharma Holdings Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02937558 | phase2 | completed | 2016-10-01 | 2018-09-01 | Xeris Pharmaceuticals | CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism |
| NCT02423980 | phase2 | completed | 2015-04-01 | 2015-05-01 | Xeris Pharmaceuticals | G-Pen™ for Hypoglycemia Rescue in T1D Patients |
| NCT03490942 | phase2 | terminated | 2018-03-15 | 2019-11-04 | Xeris Pharmaceuticals | Glucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses |
| NCT03091673 | phase3 | completed | 2017-03-27 | 2017-09-07 | Xeris Pharmaceuticals | Glucose Response of G-Pen (Glucagon Injection) in Pediatric T1D Patients |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 212097 | NDA | XERIS PHARMACEUTICALS INC |
Marketed products (6)
- GVOKE HYPOPEN
- GVOKE HYPOPEN
- GVOKE KIT
- GVOKE PFS
- GVOKE PFS
- GVOKE VIALDX